Intervention Review

You have free access to this content

Levetiracetam for neuropathic pain in adults

  1. Philip J Wiffen1,
  2. Sheena Derry1,*,
  3. R Andrew Moore1,
  4. Michael PT Lunn2

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 7 JUL 2014

Assessed as up-to-date: 3 JUL 2014

DOI: 10.1002/14651858.CD010943.pub2


How to Cite

Wiffen PJ, Derry S, Moore RA, Lunn MPT. Levetiracetam for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD010943. DOI: 10.1002/14651858.CD010943.pub2.

Author Information

  1. 1

    University of Oxford, Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), Oxford, Oxfordshire, UK

  2. 2

    National Hospital for Neurology and Neurosurgery, Department of Neurology and MRC Centre for Neuromuscular Diseases, London, UK

*Sheena Derry, Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, OX3 7LE, UK. sheena.derry@ndcn.ox.ac.uk.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 7 JUL 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Falah 2012 {published data only}
Finnerup 2009 {published data only}
Holbech 2011 {published data only}
Jungehulsing 2013 {published data only}
NCT00160511 {unpublished data only}
  • A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN). www.clinicaltrials.gov 2013. [NCT: 00160511]
Vilholm 2008 {published data only}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Rossi 2009 {published data only}

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
NCT00156689 {unpublished data only}
  • A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy. www.clinicaltrials.gov 2008. [NCT: 00156689]

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Apkarian 2011
AUREF 2012
  • PaPaS author and referee guidance. http://papas.cochrane.org/papas-documents (accessed 22 January 2013).
Baron 2010
Baron 2012
Bouhassira 2008
Derry 2012
Derry 2013
Dworkin 2008
Elbourne 2002
Gustorff 2008
Hall 2008
Higgins 2011
  • Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jadad 1996
Jensen 2011
  • Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204-5. [DOI: 10.1016/j.pain.2011.06.017]
Kalso 2013
Katusic 1991
  • Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945-1984. Neuroepidemiology 1991;10:276-81.
Khaliq 2007
Khan 1996
Koopman 2009
L'Abbé 1987
Lunn 2014
Mbzivo 2012
McQuay 1998
  • McQuay H, Moore R. An evidence-based resource for pain relief. Oxford: Oxford University Press, 1998.
McQuay 2007
  • McQuay HJ, Smith LA, Moore RA. Chronic Pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. [ISBN: 978-1-84619-063-6]
Moisset 2007
Moore 1998
Moore 2008
  • Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]
Moore 2009
Moore 2010a
Moore 2010b
Moore 2010c
  • Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: doi:10.1136/ard.2009.107805]
Moore 2010d
Moore 2010e
Moore 2011
  • Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2]
Moore 2011b
  • Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: doi:10.1016/j.pain.2010.11.030]
Moore 2011c
Moore 2012a
Moore 2012b
Moore 2013a
  • Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2013;March 6:Epub ahead of print. [DOI: 10.1111/papr.12050]
Moore 2013b
Moore 2013c
Moore 2013d
  • Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2013;June 3:Epub. [DOI: 10.1002/j.1532-2149.2013.00341.x]
NICE 2013
  • Draft Guidance. National Institute for Health and Clinical Excellence (2013) Neuropathic pain – pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. National Institute for Health and Care Excellence Accessed August 2013. [www.nice.org.uk/nicemedia/live/13566/64189/64189.pdf ]
O'Brien 2010
O'Connor 2009
Rappaport 1994
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Soni 2013
  • Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: A community-based study. Arthritis & Rheumatism 2013;April 1:Epub ahead of print. [DOI: 10.1002/art.37962]
SPC 2013
  • electronic Medicines Compendium: Keppra. www.medicines.org.uk/emc/medicine/16231/SPC/Keppra+250%2c500%2c750+and+1000+mg+film-coated+Tablets%2c+100+mg+ml+oral+solution+and+100+mg+ml+concentrate+for+solution+for+infusion/ Accessed 02.12.2013.
Straube 2008
Straube 2010
  • Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia--responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [doi: 10.1186/1471-2474-11-150]
Torrance 2006
Tracey 2011
Treede 2008
van Hecke 2014
von Hehn 2012
Vos 2012
Wakita 2013
  • Wakita M, Kotani N, Kogure K, Akaike N. Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn2+-dependentGABAA receptor-mediated presynaptic modulation. Journal of Pharmacology and Experimental Therapeutics 2013;Nov 20:Epub ahead of print. [PUBMED: 24259680]
Wiffen 2013